Effectiveness and safety of pegylated liposomal doxorubicin versus epirubicin as neoadjuvant or adjuvant chemotherapy for breast cancer: a real-world study

Table 5 Three-year DFS rate of adjuvant chemotherapy

	PLD group	Epirubicin group	P value	Rate difference (PLD group-epirubicin group), 95%CI
Before PSM, n	292	647
3-year DFS, % [95%CI]	96.0% [93.2, 98.7]	95.1% [93.1, 97.1]	0.6516	0.85 [−2.54, 4.24]
After PSM, n	201	402
3-year DFS, % [95%CI]	94.9% [91.1, 98.6]	95.4% [93.0, 97.9]	0.5684	−0.55 [−5.02, 3.92]

ISSN: 1471-2407